Category: Publications
Search News
Mouse models of ovarian cancer
27th January 2020
Research led by the Barts Cancer Institute, Queen Mary University of London, has revealed that mouse models of the most common and deadly form of ovarian cancer, high-grade serous ovarian cancer, can effectively replicate the disease in humans. These models provide useful pre-clinical tools that may help to determine which patients are likely to respond to particular treatments.
Read more
Protein network rewiring in cancer
20th January 2020
Research published in Nature Biotechnology has identified new ways to analyse the complexity of the internal workings of normal cells and cancer cells. The study highlights how genetic changes rewire the biochemistry of cancer cells and may aid in identifying new drug targets specific for a patient’s disease.
Read more
Tackling resistance in skin cancer
13th January 2020
Researchers have found that melanoma cells fight anti-cancer drugs by changing their internal skeleton (cytoskeleton) – opening up a new therapeutic route for combating skin and other cancers that develop resistance to treatment.
Read more
IBIS-II – new results from international breast cancer study
12th December 2019
The Queen Mary University of London professor leading an international breast cancer study says anastrozole – rather than tamoxifen – should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease.
Read more
First steps towards a vaccine for pancreatic cancer
26th November 2019
Researchers from Barts Cancer Institute and Zhengzhou University have developed a personalised vaccine system that could ultimately delay the onset of pancreatic cancer. The study reports the team’s work with a pre-clinical model using mice, and provides strong proof-of-concept for the creation of a vaccine for cancer prevention in individuals at high risk of developing this disease.
Read more
Call for genetic screening for all breast cancer patients
3rd October 2019
A lifetime model evaluating the financial, health and social impact of multigene testing at diagnosis for all breast cancer patients was found to save lives and be extremely cost-effective for both UK and US health systems.
Read more